Laboratory of Stem Cells and Cancer, Université Libre de Bruxelles (ULB), Brussels, Belgium.
WELBIO, Université Libre de Bruxelles (ULB), Bruxelles, Belgium.
EMBO Mol Med. 2020 Nov 6;12(11):e13347. doi: 10.15252/emmm.202013347. Epub 2020 Oct 16.
Merkel cell carcinoma (MCC) is a rare but very aggressive neuroendocrine cancer of the skin, with very limited therapeutic options. Although immunotherapy is effective in some cases, there is an unmet need for new therapeutic approaches in MCCs. In this issue of EMBO Molecular Medicine, Leiendecker et al identify a selective vulnerability of MCC for inhibitors of the lysine-specific histone demethylase 1A (LSD1). LSD1 inhibitors promote differentiation of tumor cells toward normal Merkel cell fate, impairing tumor cell growth in vivo, and opening new avenues for the treatment of patients with MCC.
默克尔细胞癌（Merkel cell carcinoma，MCC）是一种罕见但非常侵袭性的皮肤神经内分泌癌，治疗选择非常有限。虽然免疫疗法在某些情况下有效，但 MCC 仍需要新的治疗方法。在本期的《EMBO 分子医学》中，Leiendecker 等人发现赖氨酸特异性组蛋白去甲基化酶 1A（lysine-specific histone demethylase 1A，LSD1）抑制剂对 MCC 具有选择性杀伤作用。LSD1 抑制剂可促进肿瘤细胞向正常 Merkel 细胞命运分化，抑制肿瘤细胞在体内生长，为治疗 MCC 患者开辟了新的途径。
